Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

BofA Securities has recently resumed Eli Lilly And Co (LLY) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the ...

Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

We examine trademark litigation data to reveal how rival drugmakers Novo Nordisk and Eli Lilly are aggressively enforcing ...

FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...